HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Injunction Closes Another Supplement Firm: Health And Wellness Industry News

This article was originally published in The Rose Sheet

Executive Summary

Mannatech slumps on Americas downturn; MusclePharm navigates bumps in turnaround; kratom recalls updated; and FDA, DoJ shutter another supplement firm

You may also be interested in...

Kratom Industry Offers Own Standards As Another Firm Warned About FDA Rules

Warning to contract manufacturer Avalon Packaging points out all but one of the problems that have dogged the kratom industry, including saying the herb's safety for its intended use should be proved to FDA before it is used in supplements and noting GMP problems, an area a kratom industry trade group discusses specifically in the standards program also published Nov. 20. While FDA also notes another problem kratom industry has wrestled with over past year, salmonella contamination, it doesn't allege Avalon's products are opioids.

NDI Notification Estimate Unchanged: Health And Wellness Industry News

Biotek gets FDA's own-labeler lesson; MyNicNaxs shut down after ignoring warning; and FDA sticks with NDI notification cost estimate.

FDA Targets Riddhi GMP Failures: Health And Wellness Industry News In Brief

Complaint filed to shut down Riddhi USA; GOED introduces guidelines to assist industry in preventing oxidation of EPA/DHA oils; UK says B-Life breached ad codes by claiming its ADrop water ionizer can improve health, specifically diabetes; and more health and wellness news in brief.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts